Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study.

Although no statistical significance was reached, there was a numerical trend toward higher Ki-67 values in tumors with poorer response: the mean Ki-67 ranged from 12.3 ± 10.0% in stable tumors to 17.8 ± 11.1% in those showing reduction, reaching 20% in progressive cases.

also in 708 other papers

In our series, Ki-67 and p53 expression alone did not reach statistical significance in predicting the tumor response, corroborating previous evidence that conventional proliferation markers may be insufficient when evaluated independently [ 31 , 32 ].

also in 61,332 other papers